Vaxcyte (PCVX) Cash from Operations (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash from Operations data on file, last reported at 280625000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 280625000.0, down 68.77% year-over-year; the trailing twelve-month figure through Mar 2026 was 769928000.0 (down 67.46% YoY), and the FY2025 annual result was 655577000.0, down 44.84% from the prior year.
• Cash from Operations slipped to 280625000.0 in Q1 2026 per PCVX's latest filing, from 224832000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 27702000.0 in Q1 2022 and troughed at 280625000.0 in Q1 2026.
• A 5-year average of 109189176.47 and a median of 111401000.0 in 2024 frame the typical range for Cash from Operations.
• On a YoY basis, Cash from Operations climbed as much as 13.52% in 2024 and fell as far as 233.66% in 2024.
• A 5-year view of Cash from Operations shows it stood at 65221000.0 in 2022, then plunged by 97.5% to 128810000.0 in 2023, then grew by 13.52% to 111401000.0 in 2024, then slumped by 101.82% to 224832000.0 in 2025, then declined by 24.82% to 280625000.0 in 2026.
• Business Quant data shows PCVX's Cash from Operations at 280625000.0 in Q1 2026, 224832000.0 in Q4 2025, and 143305000.0 in Q3 2025.